%0 Journal Article
%A León-González, Antonio J
%A Jiménez-Vacas, Juan M
%A Fuentes-Fayos, Antonio C
%A Sarmento-Cabral, Andre
%A Herrera-Martínez, Aura D
%A Gahete, Manuel D
%A Luque, Raúl M
%T Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers.
%D 2021
%U https://hdl.handle.net/10668/28264
%X Metabolic syndrome is associated with chronic diseases, including type 2 diabetes, cardiovascular diseases, and cancer. This review summarizes the current evidence on the antitumor effects of some relevant drugs currently used to manage metabolic-related pathologies (i.e. insulin and its analogs, metformin, statins, etc.) in endocrine-related cancers including breast cancer, prostate cancer, pituitary cancer, ovarian cancer, and neuroendocrine neoplasms. Although current evidence does not provide a clear antitumor role of several of these drugs, metformin seems to be a promising chemopreventive and adjuvant agent in cancer management, modulating tumor cell metabolism and microenvironment, through both AMP-activated protein kinase-dependent and -independent mechanisms. Moreover, its combination with statins might represent a promising therapeutic strategy to tackle the progression of endocrine-related tumors. However, further studies are needed to endorse the clinical relevance of these drugs as adjuvants for cancer chemotherapy.
%K Cancer
%K insulin
%K metabolic syndrome
%K metformin
%K statins
%~